Form 4: Seelos Therapeutics CFO Acquires Shares Under Employee Stock Purchase Plan

Michael Joseph Golembiewski, CFO of Seelos Therapeutics, acquired 417 shares of common stock under the company's Employee Stock Purchase Plan on February 29, 2024.

Summary

• On February 29, 2024, Michael Joseph Golembiewski, the Chief Financial Officer of Seelos Therapeutics, acquired 417 shares of common stock.
• The shares were purchased under the company's 2020 Employee Stock Purchase Plan at a price of $1.097 per share.
• Following the transaction, Golembiewski directly owns 86,869 shares of Seelos Therapeutics common stock.
• The reported share amounts reflect a 1-for-30 reverse stock split that was effective on November 28, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, and while insider buying can be seen as positive, it's a small amount of shares purchased through an employee stock purchase plan.

Positives

• The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the actions of company executives regarding their holdings in the company's stock.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, primarily providing transparency to shareholders regarding insider activity.

Key Dates

Keywords

Seelos Therapeutics, SEEL, Michael Golembiewski, CFO, Employee Stock Purchase Plan, Stock Acquisition, Form 4, Reverse Stock Split